Tandem Diabetes Care, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount
Tandem Diabetes Care, Inc. (TNDM) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2026-02-19
- Tandem Diabetes Care, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Tandem Diabetes Care, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2023 was $14.94M, a 129.18% increase from fiscal 2022.
- Tandem Diabetes Care, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2022 was $6.52M.
- Tandem Diabetes Care, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2021 was $0.00.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2026-02-19 |
| 2023-12-31 | $14.94M 10-K · filed 2026-02-19 |
| 2022-12-31 | $6.52M 10-K · filed 2025-02-26 |
| 2021-12-31 | $0.00 10-K · filed 2024-02-21 |
| 2020-12-31 | $0.00 10-K · filed 2023-02-22 |
| 2014-12-31 | -$646.00K 10-K · filed 2015-02-24 |
| 2013-12-31 | -$649.00K 10-K · filed 2015-02-24 |
| 2012-12-31 | $209.00K 10-K · filed 2015-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |
| ANGIODYNAMICS INC (ANGO) | United States | $0.632B | -13.02 |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B |